West Pharmaceutical Services, Inc. — Q1 2019 Form 10-Q Summary
Business context and reporting period
West designs and manufactures containment, packaging, drug-delivery and contract-manufacturing products for biologic, generic, pharmaceutical, diagnostic and medical-device customers. The filing covers the three months ended March 31, 2019, compared with the first quarter of 2018. Reportable segments are Proprietary Products and Contract-Manufactured Products.
Financial performance and key metrics
- Net sales: $443.5 million, up 6.7% from $415.7 million. Excluding foreign-currency translation, sales increased 11.4%.
- Segment sales: Proprietary Products rose 4.3% reported and 9.4% excluding currency; Contract-Manufactured Products rose 15.3% reported and 18.9% excluding currency.
- Gross profit: $146.8 million, up 9.2%; gross margin increased to 33.1% from 32.3%.
- Operating profit: $70.7 million, up 32.4%; operating margin increased to 15.9% from 12.8%. Adjusted operating profit, excluding unallocated restructuring items, was $71.3 million, with a 16.1% margin.
- Net income: $55.4 million, up from $43.6 million. Diluted earnings per share increased to $0.73 from $0.58.
- Effective tax rate: 23.1%, compared with 23.3%.
- Operating cash flow: $47.6 million, compared with $45.0 million.
- Capital expenditures: $28.8 million, compared with $28.0 million.
- Free cash flow proxy: Operating cash flow less capital expenditures was approximately $18.8 million.
- Cash and liquidity: Cash and equivalents were $265.5 million at March 31, 2019, down from $337.4 million at year-end 2018. Available borrowing capacity was $269.4 million.
- Debt: Total debt was $195.5 million, substantially unchanged from $196.1 million at December 31, 2018. The company reported compliance with all debt covenants.
- Balance sheet: Total assets were $2.04 billion and equity was $1.37 billion. Working capital was $566.5 million, down from $610.7 million.
- Shareholder returns: The company repurchased 800,000 shares for $83.1 million, or $103.89 per share, and declared dividends of $0.15 per share.
Material changes versus the prior comparable period
- Sales growth was driven by high-value Proprietary Products, including NovaPure, ready-to-use seals, stoppers and plungers, Envision components, pricing actions, and increased healthcare-related injection and diagnostic-device sales.
- Gross margin benefited from product mix, price increases and lower raw-material costs, partly offset by higher labor costs and the Vial2Bag recall. Contract-Manufactured Products margin declined to 14.0% from 14.8% because of product mix, labor costs and under-absorbed overhead.
- Restructuring charges declined to $0.6 million from $3.3 million. Management expects the 2018 restructuring plan to provide approximately $14.0 million of annualized savings when fully implemented.
- Other income and expense improved to $2.3 million of net income from $3.1 million of expense, primarily because of foreign-exchange gains.
- Financing cash use increased to $90.5 million from $56.9 million, principally because of higher share repurchases.
- Stock-based compensation expense increased to $6.2 million from $3.4 million.
- The company adopted ASC 842 lease accounting on January 1, 2019, recording operating lease right-of-use assets of $71.0 million and lease liabilities of $73.1 million at adoption. At March 31, operating lease liabilities totaled $77.6 million.
Guidance, outlook, risks and unusual items
- The filing does not provide explicit quantitative full-year revenue or earnings guidance.
- Management stated that cash on hand, operating cash flow and available credit are expected to meet foreseeable liquidity needs, including capital expenditures and scheduled debt payments.
- On January 24, 2019, West initiated a voluntary recall of its Vial2Bag product line because of potential unpredictable or variable dosing. The company recorded a $4.5 million provision in the quarter for potential inventory returns and related in-house inventory, following an $11.3 million product-return provision recorded in 2018. West was working to return the products to market.
- Reported earnings benefited from foreign-exchange transaction gains and a $1.4 million tax benefit related to stock-based compensation. These items may not represent recurring operating performance.
- Key risks include customer demand and inventory changes, product mix, competition, regulatory approval and commercialization of customer products, reliance on third-party suppliers including Daikyo, labor and production constraints, petroleum-based raw-material costs, foreign-exchange movements, supply-chain disruptions, cybersecurity and healthcare legislation.
- The company reported no material changes to previously disclosed risk factors, no legal proceedings requiring disclosure, and no material changes to commitments and contingencies.
- In April 2019, West acquired its distributor’s South Korean business; management stated that the acquisition was not expected to materially affect the financial statements.
Important facts for investors to verify
- Track the financial and commercial impact of the Vial2Bag recall, including return provisions, product relaunch timing and customer demand.
- Separate recurring operating improvement from foreign-exchange gains, restructuring reductions and stock-compensation tax benefits.
- Monitor conversion of earnings into cash, especially accounts receivable and inventory growth and the effect of continued share repurchases.
- Review the new $300.0 million revolving credit facility, its March 2024 maturity, covenant requirements and foreign-currency borrowings.
- Assess whether Proprietary Products growth and margin expansion offset weaker Contract-Manufactured Products margins and higher labor or overhead costs.
- Confirm the effect of ASC 842 on leverage, liquidity presentation and future lease obligations.